= per oral; PV = prime vaccin ation; UA = urinalysis; VC = vital capacity. Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 33 Table 2b. Schedule of Procedures – Low-dose Cy/CRS -207 and Pemetrexed/Cisplatin [Cohort 2] Nominal Weeks (Wk)a Wk 1 Wk 3 Wk 5 Wk 8 Wk 11 Wk 14 Wk 17 Wk 20 Wk 23 Wk 26 Wk 30 Follow -up: 4 wks after EOC then every 8 wks Visit ID SCR XP1 PV1 XP2 PV2 CY1 CY2 CY3 CY4 CY5 CY6 XB1 BV1 XB2 BV2 EOC FU/EOS Cycle Study Days (-28) 1 2 3 9 1 2 3 9 1 1 1 1 1 1 1 2 3 9 1 2 3 9 1 1 Visit Windows (days) - - - ±1 - - - ±1 - - - - - - - - - ±1 - - - ±1 +7 ±7 Informed consent X Inclusion/exclusion X Medical history, medication history X Cancer -related treatment X Baseline signs/symptoms X Virology screen c X Coagulation panel, UA d X Pulmonary Function Test e X X X X X X Electrocardiogram, 12 -lead X X CT, tumor assessment ; optional FDG -PETf X X X X X X Physical examination g X X X X X X X X X X X X X ECOG performance status X X X X X X X X X X X X X Vital signs, pulse oximetry, weight, and height h X X X X X X X X X X X X X X X X X X X X X Pregnancy test i X X X X X CD4 count X X Creatinine clearance j X Clinical hematology, serum chemistry k,l X X X X X X l X l X l X l X l X l X X X X X X Tumor marker(s) m X X X X X X X X X X X X Concomitant medications, AEs n X X X X n X X X X n X X X X X X X X X X n X X X X n X X PBMC o X X X X X X Serum for Lm/mesothelin immunity p X X X X X X X X X X HLA -typing q X Archival Tissue X r Tumor biopsy (optional) s X X X X Antibiotics t X X Blood for CRS -207 testing Xv Study Drug Administration Cycloph osphamidew X X X X Xw CRS -207 x, y X X X X Xw Pemetrexed/cisplatin z, aa X X X X X X Aduro Biotech , Inc. Protocol ADU -CL-02-v8 CRS -207 with Pemetrexed and Cisplatin Version 8, 08 March 2018 Page 34 a Study schedule and timing displayed is based on the subject completing the full treatment regimen of 6 chemotherapy cycles. However, subjects may receive Cy/CRS -207 boost vaccinations if they complete between 4 -6 cycles in which case the visit timing will be modified. If CRS- 207 doses or chemotherapy cycles are delayed, subsequent dosing schedule will be adjusted according to the delayed dose(s). b Follow -up visit to occur 4 weeks after EOC then every 8 weeks until treatment discontinuation. EOS Visit will occur within 4 weeks after the last dose of study drug or prior to commencing the new therapy. If the EOT visit occurs earlier than 4 weeks, a safety follow -up telephone call on Day 28 (+/-7 days) is required; document contact in the study records. c Virology screen will be performed if one has not been done within 14 days before screening: HIV antibody, hepatitis B surface antigen, and hepatitis C antibody (exception: clear evidence of natural immunity, immunity subsequent to vaccination, or successful eradication of the virus following antiviral therapy); additional virology may also be evaluated. d Coagulation panel includes the following: prothrombin time ( PT), international normalized ratio of prothrombin time ( INR), activated partial thromboplastin time ( APTT) ; UA includes the following: bilirubin, blood, glucose, ketones, leukocytes, nitrite, pH, protein, specific gravity. e Pulmonary function tests to include VC, FVC and FEV 1.